已核实 DOI PubMed 相关产品: 1

Mucus-Penetrable Biomimetic Nanoantibiotics for Pathogen-Induced Pneumonia Treatment

Journal 2024 · IF 15.8 · 发表于 2024 年 11 月 1 日
作者: Yue Wang,Qihang Ding,Gongcheng Ma,Zhiwei Zhang,Jiaqi Wang,Chang Lu,Chunbai Xiang,Kun Qian,Jun Zheng,Yaming Shan,Pengfei Zhang,Zhen Cheng,Ping Gong,Qi Zhao
阅读全文 在 PubMed 查看

摘要

Bacterial pneumonia has garnered significant attention in the realm of infectious diseases owing to a surge in the incidence of severe infections coupled with the growing scarcity of efficacious therapeutic modalities. Antibiotic treatment is still an irreplaceable method for bacterial pneumonia because of its strong bactericidal activity and good clinical efficacy. However, the mucus layer forming after a bacterial infection in the lungs has been considered as the “Achilles’ heels” facing the clinical application of such treatment. Herein, traceable biomimetic nanoantibiotics (BioNanoCFPs) were developed by loading indacenodithieno[3,2-b]thiophene (ITIC) and cefoperazone (CFP) in nanoplatforms coated with natural killer (NK) cell membranes. The BioNanoCFP exhibited excellent demonstrated mucus-penetrating abilities, facilitating their arrival at the infection site. The presence of Toll-like receptors in the NK cell membrane rendered the BioNanoCFP with the capability to recognize pathogen-associated molecular patterns within bacteria, allowing precise targeting of bacterial colonization sites and achieving substantial therapeutic efficacy. Overall, our findings demonstrate the viability and desirability of using NK cell membrane-mediated drug delivery as a promising strategy for precision treatment.

本研究中使用的阿拉丁产品

1 款产品在本文中被引用